Abstract
cAMP markedly increases α1B adrenergic receptor (α1B-AR) expression in FRTL-5 and PC C13 rat thyroid cells, DDT1MF-2 smooth muscle cells, primary rat hepatocytes, and K9 rat liver cells. Here, we used DDT1MF-2 cells to evaluate further the mechanisms by which cAMP stimulates α1B-AR expression. Receptor binding assays, Northern blotting, and nuclear run-on analyses demonstrated that forskolin (1 μm) in the presence of isobutylmethylxanthine (0.25 mm) increased α1B-AR numbers, mRNA level, and gene transcription rate by 2.3 ± 0.2-, 2.5 ± 0.3-, and 3.5 ± 0.2-fold over control, respectively. Dibutyryl cAMP (1 mm) plus isobutylmethylxanthine (0.25 mm) also enhanced α1B-AR density by 2.7 ± 0.1-fold over control. Further experiments demonstrated that the induction of α1B-AR by forskolin requires new protein synthesis and is protein kinase A dependent. In DDT1MF-2 cells transfected with α1B-AR gene P2 promoter/CAT constructs, both forskolin and dibutyryl cAMP significantly increased P2 promoter activity. The P2 promoter region of the rat α1B-AR gene (−813 to −432) contains a cAMP response element (CRE) (−444 to −437) and an AP2 binding site (−647 to −638). Mutations in either one of these elements alone led to a decrease in both basal and cAMP-induced P2 promoter activity. Mutations in both elements caused a further inhibition of basal transcription and a complete block of cAMP-induced P2 promoter activity. Direct binding of purified activator protein 2 (AP2) to the AP2 element in the P2 promoter was reported previously. Gel mobility shift and supershift assays using liver nuclear extracts from either rat liver or DDT1MF-2 cells demonstrated that the CRE in the α1B-AR gene bound CRE binding protein. These data indicate that both the CRE and the AP2 element in the P2 promoter contribute to basal as well as cAMP-induced transcription of the α1B-AR gene in DDT1MF-2 cells.
Footnotes
- Received April 21, 1997.
- Accepted September 4, 1997.
-
Send reprint requests to: Dr. Bin Gao, Dept. of Pharmacology & Toxicology, MCV Station, Box 980613, Richmond, VA 23298. E-mail: bgao{at}hsc.vcu.edu
-
This work was supported in part by Grant IN-105U from the American Cancer Society and Grant J-379 from the Thomas F. Jeffress and Kate Miller Jeffress Memorial Trust.
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|